Thomas K. Equels Purchases 60,110 Shares of AIM ImmunoTech Inc. (NYSE:AIM) Stock

AIM ImmunoTech Inc. (NYSE:AIM) CEO Thomas K. Equels bought 60,110 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were purchased at an average price of $0.18 per share, with a total value of $10,819.80. Following the acquisition, the chief executive officer now directly owns 1,552,968 shares in the company, valued at approximately $279,534.24. This trade represents a 4.03 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

AIM ImmunoTech Stock Down 0.8 %

Shares of AIM ImmunoTech stock opened at $0.21 on Friday. The stock has a 50-day moving average price of $0.26 and a 200 day moving average price of $0.33. The company has a market cap of $13.39 million, a P/E ratio of -0.45 and a beta of -0.36. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 0.05. AIM ImmunoTech Inc. has a 1 year low of $0.16 and a 1 year high of $0.62.

Institutional Investors Weigh In On AIM ImmunoTech

A hedge fund recently bought a new stake in AIM ImmunoTech stock. Armistice Capital LLC purchased a new position in shares of AIM ImmunoTech Inc. (NYSE:AIM) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech at the end of the most recent reporting period. 12.02% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Ascendiant Capital Markets decreased their price target on AIM ImmunoTech from $5.25 to $5.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Maxim Group decreased their price target on AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, October 22nd.

About AIM ImmunoTech

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).